Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||CPI-455 + Lapatinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CPI-455||CPI-455 is an inhibitor of KDM5A, KDM5B, and KDM5C, which may reduce cell survival, in particular those cells that are considered drug resistant (PMID: 27214401, PMID: 31238504).|
|Lapatinib||Tykerb||Lapatinib Ditosylate||EGFR Inhibitor (Pan) 54 HER2 Inhibitor 32||Tykerb (lapatinib) reversibly inhibits ERBB2 (HER2) and EGFR, resulting in decreased downstream signaling and potentially leading to reduced tumor growth (PMID: 22477724). Tykerb (lapatinib) is FDA approved for ERBB2 (HER2)-positive (overexpressing) breast cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|